Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Declines By 33.9%

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totalling 109,000 shares, a drop of 33.9% from the December 31st total of 164,900 shares. Currently, 2.7% of the company’s stock are sold short. Based on an average daily trading volume, of 1,800,000 shares, the short-interest ratio is presently 0.1 days.

Virax Biolabs Group Price Performance

Shares of NASDAQ:VRAX remained flat at $1.69 during midday trading on Friday. 119,104 shares of the stock traded hands, compared to its average volume of 351,737. Virax Biolabs Group has a one year low of $0.60 and a one year high of $9.00. The business’s 50 day moving average price is $2.03 and its 200 day moving average price is $2.21.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.